Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin
Abstract
Inhalational anthrax is rare and clinical experience limited. Expert guidelines recommend treatment with combination antibiotics including protein synthesis-inhibitors to decrease toxin production and increase survival, although evidence is lacking.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 22, 2020
- Source ID
- 10.1093/infdis/jiaa365
Entities
People
- Adrian R. Woolfitt
- Anne E Boyer
- Arthur M. Friedlander
- Brandon C Somerville
- Chris W Schellhase
- Christopher K Cote
- Christopher P. Klimko
- David P. Fetterer
- Donald J. Chabot
- Jeremy A. Miller
- John R. Barr
- Mary E. Wright
- Nancy A. Twenhafel
- Nicholas J. Vietri
- Steven A. Tobery
- Susham S. Ingavale
Organizations
- Centers for Disease Control and Prevention
- Defense Threat Reduction Agency
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- Uniformed Services University of the Health Sciences
- United States Army Medical Research Institute of Infectious Diseases